The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
REVIVE phase II final results: Rusfertide in patients with polycythemia vera
|
Preliminary results from the phase II REVIVE trial (NCT04057040) demonstrated that rusfertide, a novel hepcidin mimetic peptide, was superior to placebo in achieving hematocrit levels <45% in patients with PV. Final results from the three-part REVIVE trial were presented by Aaron T. Gerds at the 66th ASH Annual Meeting and Exposition.1 A total of 70 patients were enrolled in Part 1, 59 in Part 2, and 58 continued to Part 3.1 |
| Key learnings |
| Rusfertide demonstrated superiority over placebo in achieving the primary endpoint of hematocrit control without TP in Part 2 (69.2% vs 14.8%; p < 0.0001). |
| Hematocrit control <45% was consistently maintained with rusfertide for ≥3 years compared with placebo. The use of TP reduced after the initiation of rusfertide treatment. |
|
According to MPN-SAF, rusfertide improved symptoms of fatigue (n = 20), early satiety (n = 13), abdominal discomfort (n = 9), inactivity (n = 12), problems with concentration (n = 14), night sweats (n = 11), and itching (n = 13) at the end of Part 3 (p < 0.05 each). |
| Grade 3 TEAEs occurred in 25.7% of patients and SAEs in 26% of patients; most were unrelated to the treatment. After ≥150 patient-years of rusfertide exposure, 11 patients reported malignancies. Seven thrombotic events occurred in six patients with high-risk PV. |
| Final results from the phase II REVIVE trial show that rusfertide ±CRT controlled erythrocytosis, provided long-term durable hematocrit control, and decreased the need for TP in patients with PV. Ongoing trials evaluating the safety and efficacy of rusfertide include phase II THRIVE OLE (NCT06033586) and phase III VERIFY (NCT05210790). |
Abbreviations: ASH, American Society of Hematology; CRT, cytoreductive therapy; MPN-SAF, Myeloproliferative Neoplasm Symptom Assessment Form; PV, polycythemia vera; SAE, serious adverse event; TEAE, treatment-emergent adverse event; TP, therapeutic phlebotomy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
